BACKGROUND: There is uncertainty about how patients with Crohn's colitis should be monitored for colorectal cancer (CRC). By analogy to ulcerative colitis, regular colonoscopy with biopsies for dysplasia has been used. We describe the occurrence of dysplasia and DNA aneuploidy in a cohort of patients with Crohn's colitis. METHODS: In all, 245 patients with extensive colitis (225 with a firm diagnosis of Crohn's disease, and 20 diagnosed as indeterminate colitis) at Stockholm Söder Hospital and Karolinska University Hospital, Huddinge were included. They were followed with regular colonoscopies with biopsies both for dysplasia and DNA aneuploidy. The cumulative occurrence of DNA aneuploidy and dysplasia was estimated using Kaplan-Meier curves. Time sequences and interactions between DNA aneuploidy, dysplasia, and CRC were studied using Cox regression analysis, adjusted for age, sex, and age at diagnosis. RESULTS: During a median follow-up time of 9.2 person-years, DNA aneuploidy was found in 53 patients (22%), with 10 patients having multifocal aneuploidy and high S-phase values. Dysplasia was found in 42 patients (17%), 10 having multifocal dysplasia. Relative risk (RR) of dysplasia given DNA aneuploidy was 5.3 (95% confidence interval [CI] 2.3-12). RR of CRC given dysplasia was 10 (95% CI 2-50), and RR of CRC given aneuploidy was 1.5 (95% CI 0.3-9.3). CONCLUSIONS: Dysplasia and DNA aneuploidy including S-phase analysis may complement stratification of patients with Crohn’s
BACKGROUND: There is uncertainty about how patients with Crohn's colitis should be monitored for colorectal cancer (CRC). By analogy to ulcerative colitis, regular colonoscopy with biopsies for dysplasia has been used. We describe the occurrence of dysplasia and DNA aneuploidy in a cohort of patients with Crohn's colitis. METHODS: In all, 245 patients with extensive colitis (225 with a firm diagnosis of Crohn's disease, and 20 diagnosed as indeterminate colitis) at Stockholm Söder Hospital and Karolinska University Hospital, Huddinge were included. They were followed with regular colonoscopies with biopsies both for dysplasia and DNA aneuploidy. The cumulative occurrence of DNA aneuploidy and dysplasia was estimated using Kaplan-Meier curves. Time sequences and interactions between DNA aneuploidy, dysplasia, and CRC were studied using Cox regression analysis, adjusted for age, sex, and age at diagnosis. RESULTS: During a median follow-up time of 9.2 person-years, DNA aneuploidy was found in 53 patients (22%), with 10 patients having multifocal aneuploidy and high S-phase values. Dysplasia was found in 42 patients (17%), 10 having multifocal dysplasia. Relative risk (RR) of dysplasia given DNA aneuploidy was 5.3 (95% confidence interval [CI] 2.3-12). RR of CRC given dysplasia was 10 (95% CI 2-50), and RR of CRC given aneuploidy was 1.5 (95% CI 0.3-9.3). CONCLUSIONS:Dysplasia and DNA aneuploidy including S-phase analysis may complement stratification of patients with Crohn’s
Authors: Chang-Ho R Choi; Ibrahim Al Bakir; Ailsa L Hart; Trevor A Graham Journal: Nat Rev Gastroenterol Hepatol Date: 2017-02-08 Impact factor: 46.802
Authors: Ana I Robles; Giovanni Traverso; Ming Zhang; Nicholas J Roberts; Mohammed A Khan; Christine Joseph; Gregory Y Lauwers; Florin M Selaru; Maria Popoli; Meredith E Pittman; Xiquan Ke; Ralph H Hruban; Stephen J Meltzer; Kenneth W Kinzler; Bert Vogelstein; Curtis C Harris; Nickolas Papadopoulos Journal: Gastroenterology Date: 2016-01-05 Impact factor: 22.682
Authors: Joel Pekow; Katherine Meckel; Urszula Dougherty; Haider I Haider; Zifeng Deng; John Hart; David T Rubin; Marc Bissonnette Journal: Oncotarget Date: 2018-04-17
Authors: Ann-Marie Baker; William Cross; Kit Curtius; Ibrahim Al Bakir; Chang-Ho Ryan Choi; Hayley Louise Davis; Daniel Temko; Sujata Biswas; Pierre Martinez; Marc J Williams; James O Lindsay; Roger Feakins; Roser Vega; Stephen J Hayes; Ian P M Tomlinson; Stuart A C McDonald; Morgan Moorghen; Andrew Silver; James E East; Nicholas A Wright; Lai Mun Wang; Manuel Rodriguez-Justo; Marnix Jansen; Ailsa L Hart; Simon J Leedham; Trevor A Graham Journal: Gut Date: 2018-07-10 Impact factor: 23.059